NIPENT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NIPENT (NIPENT).
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
| Metabolism | Primarily metabolized by the liver via deamination by adenosine deaminase (ADA). |
| Excretion | Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%. |
| Half-life | Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments. |
| Protein binding | Approximately 90-95% bound to serum albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.4 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Not applicable; Nipent is only administered intravenously with 100% bioavailability via that route. Oral bioavailability is negligible and not clinically relevant. |
| Onset of Action | Intravenous administration: onset of clinical effect (immunosuppression) occurs within 2-4 hours after infusion. |
| Duration of Action | The immunosuppressive effect persists for 12-24 hours post-dose, with recovery of lymphocyte counts typically occurring within 24-48 hours. |
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated if creatinine clearance < 60 mL/min. For ClCr 60-90 mL/min: reduce dose to 2.5 mg/m2. Not recommended if ClCr < 60 mL/min. |
| Liver impairment | No specific dose adjustment guidelines for Child-Pugh class A or B. Use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability. |
| Pediatric use | Safety and efficacy not established in pediatric patients <18 years. No recommended weight-based dosing. |
| Geriatric use | No specific dose adjustments recommended for elderly based on age alone; monitor renal function closely as older patients are more likely to have decreased creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NIPENT (NIPENT).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio unknown; pentostatin is excreted in human milk with potential for serious adverse reactions in nursing infants. |
| Teratogenic Risk | Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppression, growth restriction). |
| Fetal Monitoring |
■ FDA Black Box Warning
WARNING: NIPENT (pentostatin) can cause severe bone marrow suppression, leading to neutropenia, thrombocytopenia, and anemia. Fatal hemorrhagic events and infections have occurred. Use with caution in patients with impaired renal function.
| Serious Effects |
["Hypersensitivity to pentostatin or any component of the formulation","Severe hepatic impairment","Pregnancy (risk of fetal harm)"]
| Precautions | ["Bone marrow suppression: monitor blood counts regularly","Renal toxicity: assess renal function before and during therapy","Hepatotoxicity: monitor liver function tests","Pulmonary toxicity: observe for signs of pneumonitis","Embryofetal toxicity: advise patients of reproductive potential to use effective contraception","Increased risk of infection: avoid live vaccines"] |
Loading safety data…
| Complete blood counts (CBC) with differential weekly, hepatic and renal function tests, assessment for signs of infection or bleeding, fetal ultrasound for growth and anatomy if exposure occurs. |
| Fertility Effects | May cause infertility in both males and females due to gonadal suppression; oligospermia or azoospermia reported; potential for amenorrhea or premature ovarian failure. |